메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

ReviR Therapeutics Receives Orphan Drug Designation from FDA for RTX-117 to Treat Charcot-Marie-Tooth Disease

BRISBANE, Calif. , Oct. 13, 2025 -- ReviR Therapeutics, a biotech company focused on developing novel treatments for neurogenetic diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for RTX-117, its lead investigational therapy for Charcot-Marie-Tooth disease (CMT). ReviR is preparing to launch a Phase 1 clinical trial in healthy volunteers in early 2026 to evaluate the safety, tolerability, and pharmacokinetics of RTX-117, with a Phase Ib/IIa study in CMT patients planned to follow. CMT is the most prevalent inherited p
- 김갑성 기자
- 2025-10-13 18:00
AnnJi Showcases Clinical Breakthrough of AJ201 at WMS 2025

TAIPEI, Oct. 13, 2025 -- AnnJi Pharmaceutical Co., Ltd. (AnnJi, TWSE: 7754) announced that the Phase 2a clinical result of AJ201 for spinal and bulbar muscular atrophy (SBMA, also known as Kennedy's disease) was selected as one of the seven Late-Breaking Abstracts at the World Muscle Society (WMS) 2025 International Congress in Vienna. Dr. Tahseen Mozaffar, an investigator of the study, presented the study outcome, emphasizing the therapeutic potential of AJ201 for SBMA patients. AJ201, an oral suspension of a novel curcumin analog-Rosolutamide, offers ease of use for patients with s
- 김갑성 기자
- 2025-10-13 16:03
Zhang Xinyuan, a Chinese gender relationship expert, leads thousands of women to challenge the Guinness World Records

BOAO, China, Oct. 13, 2025 -- In 2025, the Boao Forum for Asia International Conference Center in Hainan, China, hosted a highly anticipated international health event. Zhang Xinyuan,the founder and chairman of Vimi Wellness (Hangzhou) Co., Ltd. and a renowned gender relationship expert, led thousands of women from various regions in China to successfully challenge the Guinness World Record for the "largest number of women performing pelvic floor muscle exercises." This event not only demonstrated the increasing attention Chinese women are paying to their own health management but a
- 노기식 기자
- 2025-10-13 15:00
The 138th Canton Fair is Set to Open in Guangzhou on October 15

GUANGZHOU, China, Oct. 13, 2025 -- The 138th China Import and Export Fair (Canton Fair) is set to open in Guangzhou from October 15 to November 4, divided into three phases. The fair will maintain its 24-hour online presence to offer global buyers continuous access to Chinese suppliers. With an exhibition area of 1.55 million square meters, this session will feature a record 74,600 booths and more than 32,000 participating enterprises. The 138th Canton Fair marks a new milestone in both scale and innovation. For the first time, more than 10,000 exhibitors hold titles such as &q
- 김갑성 기자
- 2025-10-13 14:42
Lundbeck's bexicaserin receives Breakthrough Therapy Designation in China for the treatment of seizures in severe rare epilepsies

[ 메디채널 김갑성 기자 ] Accelerated pathway underscores urgent need for innovative solutions for patients with devastating, childhood-onset epilepsies Novel 5HT2C mechanism designed to reduce drug-resistant seizures in children and adults living with Developmental Epileptic Encephalopathies (DEEs) and improve quality of life for patients and their caregivers1 Dual Breakthrough Therapy Designation (BTD) in China and the U.S. underscores Lundbeck's mission to advance brain health and transform lives of patients with rare neurological diseases VALBY, Denmark, Oct. 13, 2025 -- Lundbeck tod
- 김갑성 기자
- 2025-10-13 14:26
ISTH marks World Thrombosis Day with urgent global call to action

[ 메디채널 김갑성 기자 ] Thrombosis is the underlying cause of 1 in 4 deaths worldwide each year. The campaign calls for crucial awareness and prevention. CHARLOTTE, N.C., Oct. 13, 2025 -- The International Society on Thrombosis and Haemostasis (ISTH) today marks World Thrombosis Day, a global movement uniting thousands of partners in more than 120 countries. This year's campaign, "From Head to Toe, Take Control. Prevent Thrombosis. Protect Your Health," calls for greater awareness of thrombosis and action to reduce its burden worldwide. Observed annually on October
- 김갑성 기자
- 2025-10-13 14:00
Singclean Anti-adhesion Technology With Professor Osama Shawki Shines at FIGO

CAPE TOWN, South Africa, Oct. 13, 2025 -- Singclean Medical, in partnership with Kayan Al-Seha Medical (KSM) and Professor Osama Shawki, successfully made its debut at the FIGO World Congress of Gynecology and Obstetrics 2025, held from October 5–9 at the Cape Town International Convention Centre. Participation at FIGO, marks a key milestone in Singclean's global strategy and growing influence in women's healthcare. Singclean Innovative Anti-adhesion Technology with Professor Osama Shawki at Figo 2025 Professor Osama Shawki's Keynote Highlights Singclean® Adhesio
- 김갑성 기자
- 2025-10-13 13:00
GC Biopharma Secures CMO Rights for Shingles Vaccine from Curevo Vaccine

YONGIN, South Korea, Oct. 13, 2025 -- GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced today that it has signed an agreement with Curevo Vaccine to secure contract manufacturing (CMO) rights for amezosvatein (development name: CRV-101), a recombinant shingles vaccine currently under clinical development. Under the terms of the agreement, GC Biopharma will be responsible for producing a portion of the commercial supply of amezosvatein for global markets. The global shingles vaccine market is currently dominated by GSK's Shingrix.
- 김갑성 기자
- 2025-10-13 12:38
Smartee Launches World's First Sleep Aligner Combining Anti-Snoring Therapy with Teeth Alignment

SHANGHAI, Oct. 13, 2025 -- Smartee Denti-Technology today announced the global launch of the Smartee Sleep Aligners, a clear aligner device designed to help manage obstructive sleep apnoea hypopnoea syndrome (OSAHS) and primary snoring (PS). The new series includes two versions: Smartee SA, which focuses on the treatment of OSAHS and PS, and Smartee SA Plus. The latter can treat OSAHS while simultaneously addressing orthodontic issues. Together, they provide clinicians with an invisible alternative to conventional OSAHS treatment therapies, offering greater comfort and compliance, and improvi
- 김갑성 기자
- 2025-10-13 09:38
Everest Medicines Announces NMPA Approval of IND Application for Tumor-Associated Antigen Cancer Vaccine EVM14

[ 메디채널 김갑성 기자 ] EVM14 becomes Everest Medicines' internally developed therapeutic mRNA cancer vaccine to receive IND approvals from both China's National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA). EVM14, an off-the-shelf therapeutic mRNA cancer vaccine, is developed based on Everest Medicines' proprietary mRNA platform. It is formulated with mRNA encoding 5 tumor-associated antigens (TAAs) and is designed to treat various squamous cell carcinomas. In preclinical studies, EVM14 demonstrated the ability to induce immune memory and prevent tumor
- 김갑성 기자
- 2025-10-13 08:47

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-10-18_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 10월 18일 18시 00분